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Aluminum Induced anemia: Pathogenesis and treatment in patients on
chronic hemodialysis. The baseline hematologic status of 27 patients
with modest degrees of aluminum overload was examined. In addition,
hematologic data were evaluated in 19 of these patients during and after
treatment with DFO. Although neither severe anemia nor microcytosis
was observed pretreatment, there was a significant correlation between
hemoglobin level and degree of aluminum burden as determined by
bone surface aluminum staining (r = —0.58; P < 0.007). Following
treatment with DFO, hemoglobin concentration increased dramatically
by 1.3 to 4.4 gIdl in eight patients but did not change in the remaining
eleven. Responders and nonresponders were similar with regard to the
degree of aluminum overload both before and after chelation therapy
but differed with regard to baseline levels of erythropoietin (higher in
responders) and degree of iron overload (greater in nonresponders).
Pretherapy levels of red cell ALA dehydratase were depressed in all
patients (32 4 vs. 56 5 U/g Hb in normals) but did not correlate with
the degree of aluminum overload and did not change with chelation
therapy. Pretherapy levels of red cell protoporphyrin were elevated in
15 of 24 patients (62%) and were higher in responders than in nonre-
sponders. Following DFO therapy, levels fell by 25 to 50% in 7 of 8
patients with elevated pretherapy values, despite the tendency in
several patients to develop iron deficiency with treatment. These results
suggest that: 1) even in the absence of severe anemia or microcytosis,
aluminum contributes to anemia in dialysis patients, an effect which
correlates with bone surface staining for aluminum but not with other
measures of aluminum overload; 2) the mechanism of the decreased red
cell production seems to involve, at least in part, a defect in iron
utilization; 3) in the absence of iron deficiency and inflammation,
elevated levels of RBC protoporphyrin may be a useful test to suggest
aluminum induced anemia but activity of red cell ALAD is not; and 4)
a positive hematopoietic response to DFO requires at least adequate
endogenous levels of erythropoietin to stimulate erythropoiesis.
Manifestations of aluminum overload in dialysis patients
include both bone disease [1, 2] and dialysis dementia [3]. Since
hemoglobin (Hb) levels fall with continued aluminum exposure
[4—6] and rise when the body burden of aluminum is decreased
by therapy with deferoxamine (DFO) [7—9] or by dialysis
against aluminum-free solutions [5, 61, it is likely that aluminum
also contributes to the pathogenesis of anemia in this popula-
tion.
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Anemia attributable to aluminum toxicity was first described
in patients with marked aluminum overload characterized by
basal serum aluminum levels over 250 pg/liter, severe bone-
fracturing osteomalacia and often, dialysis dementia. Anemia
was profound and microcytosis was common in these subjects
[4—61. While it has been proposed that anemia may be the first
manifestation of aluminum overload [5] and that microcytosis
may be a marker for this disorder [8], neither severe anemia nor
overt microcytosis have been observed in recent studies of
patients with more modest degrees of aluminum overload [7,
9—14]. Since an increase in hemoglobin concentration with DFO
therapy has been observed in some [7, 9, 13, 14] but not all of
these studies [11, 12], the question has been raised as to why
some, but not all dialysis patients have a positive hematopoietic
response to DFO. Furthermore, few studies have examined the
mechanism of the anemia in vivo or tried to identify an easily
available marker for hematopoietic toxicity due to aluminum.
The following prospective study was therefore performed to
determine which factors in dialysis patients contribute to a
positive hematopoietic response to DFO treatment, and to
evaluate the relationship between hemoglobin concentration
and degree of aluminum overload. Red cell metabolism was also
examined in an attempt to shed light on the mechanism of the
anemia and to identify a defect in red cell enzyme activity that
could serve as a biochemical marker for the hematopoietic
toxicity of aluminum.
Methods
Patient population
After giving informed consent, 28 patients, chosen because of
symptoms suggestive of renal osteodystrophy, were evaluated
with a bone biopsy and a DFO challenge test. No patient had
evidence for dialysis dementia. The study was approved by the
Institutional Review Boards of all four dialysis units from which
the patients originated. Water treated with reverse osmosis had
been utilized in all units for two to six years. At the time of
study, most patients were ingesting aluminum containing ant-
acids as their main type of phosphate binder. Patient age, years
on dialysis, number with polycystic kidney disease and number
receiving androgen or iron therapy are listed in Table 1. Seven
patients were transfusion-dependent (at least 1 unit/month for
the six month period prior to entry into the study).
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DFO treatment
After the initial evaluation, patients with bone surface alumi-
num deposition >70% received 44 weeks of therapy with DFO
(90 mg/kg once weekly) while patients with bone surface
aluminum deposition between 30% and 70% were invited to
receive 44 weeks of either DFO or placebo. Six of the original
28 patients did not receive further study (3 did not have
sufficient bone aluminum deposition, 2 refused therapy, 1 died).
Although 14 patients had 30 to 70% bone surface aluminum
staining, only three agreed to receive placebo. The remaining 11
patients in this category were given DFO therapy along with
eight patients whose initial bone surface aluminum exceeded
70%. Fifteen of these 19 treated patients had a repeat bone
biopsy after the treatment period was completed. All patients
completed at least 16 weeks of DFO therapy and thirteen
patients completed the full 44 week course of DFO. One patient
died after 24 weeks, two after 36 weeks and one at 44 weeks.
Causes of death included sepsis from infected cysts in two
patients with polycystic kidney disease, respiratory failure in
one patient with chronic lung disease and cardiac failure in one
patient. Two patients discontinued therapy after 16 weeks
because of possible drug reaction.
Clinical evaluation
Pretherapy values for Hb, MCV, MCHC and serum ferritin
were calculated as the mean of two values for each parameter
obtained two weeks apart. A pretherapy bone marrow aspirate
and biopsy was examined in 16 patients and ferrokinetic studies
performed in five. In the 19 patients treated with DFO, Hb,
MCV, MCHC, serum ferritin, and aluminum levels (before and
after each DFO treatment) were measured every two to four
weeks. Red cell protoporphyrin levels and d-aminolevulinic
acid dehydratase (ALAD) activities were also measured at the
beginning and end of therapy to determine their utility as
markers for hematopoeitic toxicity due to aluminum. Prether-
apy erythropoetin levels were measured in the 19 treated
patients to determine whether baseline levels of this hormone
influenced the hematopoietic response to DFO.
Bone biopsy samples taken from the anterior iliac crest
following tetracycline labeling were evaluated for histologic
changes as well as for the amount of aluminum quantitated as
both the percent of aluminum deposited at the bone osteoid
junction (determined by histochemical staining) and as the dry
bone aluminum content. Significant aluminum overload was
considered to be present if the increase in serum aluminum 24 to
48 hours after a DFO challenge (40 mg/kg) was >200 pg/liter
[151 and/or if >30% of the bone trabecular surface stained
positively for aluminum.
Analytic methods
Serum aluminum levels and bone aluminum content were
measured using flameless atomic absorption spectrophotometry
Table 1. Patient characteristics
Bone AIC
Patient Transfuseda Serum Al" staining
number Yrs on HD Androgen Rx Iron Rx units pg/k %
1 6 + + 0 143 87
2 7 + — 0 411 77
3 2 + — 0 374 88
4 7 + — 0 400 68
5 II + — 0 121 51
6 10 + + 0 304 36
7 15 + — 0 338 95
8 6 + + 1 533 74
9 10 + — 9 195 75
10 2 + + 0 75 0
11 8 — — 0 250 6
12 8 — — 0 288 56
13 4 — + 0 319 83
14 4 — — 4 146 64
15 4 — — 6 198 69
16 7 — — 6 437 64
17 12 — — 5 189 56
18 4 — — 6 84 60
19 4 — — 10 130 38
20d 8 + — 0 225 53
2l' 11 ÷ + 0 468 54
22" 10 + — 0 364 41
23" 10 + + 0 338 37
24d 7 — — 0 286 7
25" 8 — — 0 237 78
26" 8 — — 0 156 80
27" 12 — — 0 228 47
28d 7 — — 0 153 58
Abbreviations are: Yrs on HD, years on hemodialysis; Androgen Rx, androgen therapy (deccadurabolin
weekly); Iron Rx, iron therapy (usually intravenous imferon, 100 mg/monthly).
a Number of units transfused during the 3 month period before studyb Rise in serum aluminum level 24 to 48 hours after DFO challenge (40 mg/kg i.v.)
Percent of trabecular surface staining positive for aluminum
d Patients with polycystic kidney disease
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Hemoglobin gidi 10.3 0.3
(7.9_14.7)a
MCV fib 94 1.2
(81—103)
MCHC g/dF 33.3 0.4
(30.5—36.7)
Reticulocyte Index % 0.8 0.1
(0.2—2.3)
[3, 16] in the laboratory of Dr. Allen Alfrey. Mineral bone
histology and histochemical staining for aluminum was done
and quantitatively analyzed as described previously [17]. The
aluminum staining method was validated by energy-dispersive
x-ray analysis at the mineralization front with use of a Philips
400 transmission electron microscope with an EDAX 9100/60
energy-dispersive x-ray detector as previously described [12,
171. Serum PTH levels were determined by radioimmunoassay
using an antibody directed against the C-terminal of the PTH
red cells in the laboratory of Dr. Edward Slatopolsky [181.
Serum erythropoietin levels were measured by radioimmuno-
assay [19] in the laboratory of Gisella K. Clemmons, Ph.D.
Ferrokinetic studies were performed and the erythron iron
turnover (EIT) and red cell iron utilization at 14 days were
calculated as described by Cook et al [20]. Activities of ALAD
and levels of RBC protoporphyrin were measured according to
previously published methods [21, 22]. RBC protoporphyrin
and ALAD activities were also measured in blood samples from
18 normal hospital employees.
Statistical methods
Relationships between hematologic parameters and degree of
aluminum overload were examined by a linear regression
analysis. Differences between groups of patients were analyzed
by Student's t-test and by chi square analysis. Changes in
parameters before and after chelation therapy were analyzed by
Student's paired t-test. Data are reported as mean standard
error of the mean.
Results
Pretherapy serum and bone aluminum data (Table 1)
Initial serum aluminum levels ranged between 31 and 153
pg/liter. When significant aluminum burden is defined as either
an increase in serum aluminum of at least 200 g/1iter after a
DFO challenge [15] or deposition of aluminum on >30% of the
bone trabecular surface, all but one of the 28 patients (#10) had
evidence of significant aluminum overload (Table 1). Bone
aluminum content ranged between 28 and 225 mg/kg of dry
weight and was >50 mg/kg in all but patient #10 (normal is 3.3
2.9 SD mg/kg dry weight [161). On bone histology, six patients
had predominantly low turnover osteomalacia, eight had pre-
dominantly hyperparathyroid bone disease and 14 had mixed
uremic osteodystrophy.
Pretherapy hematologic results
Only two of 27 patents with aluminum overload had an initial
Hb level below 8.3 g/dl, the average hemoglobin of all patients
in the participating dialysis units (Table 2). There was a
significant inverse correlation (P < 0.007) between hemoglobin
and degree of aluminum overload as measured by bone surface
staining for aluminum (Fig. 1). This correlation was still signif-
icant when only iron-replete nontransfused patients were con-
sidered (N = 19; r = 0.53; P < 0.019). There was no correlation
between hemoglobin and other measures of aluminum overload
such as serum aluminum (r = 0.03), serum aluminum after a
DFO challenge (r = 0.08) or bone aluminum content (r = 0.06).
No patient had microcytosis (Table 2) nor was there evidence of
a microcytic subpopulation of red cells in 10 patients in whom
RBC size profiles were evaluated. Neither MCV nor MCHC
correlated with any index of aluminum overload or with hemo-
globin level.
The reticulocyte index was >1.6% in only one patient who
had a value of 2.3%. Ferrokinetic studies in five patients
suggested that the anemia was due to decreased red cell
production with EIT values of 0.33 to 0.42 mg/dl/day (normal =
0.35 to 0.77) and RBC iron utilization rates of 42 to 87% at 14
days (normal 68 to 100%). Analysis of initial bone marrow
aspirate and biopsy samples revealed normal cellularity in most
patients with mild hypocellularity in a few. All had normal
erythroid maturation. Ring sideroblasts were not noted and
reticulin was not increased.
ALAD activities were low (32.0 1.9 vs. 56.0 5.2 U/g Hb
in 18 normal controls) but not significantly related to any
measure of aluminum overload. RBC protoporphyrin was
Table 2. Pretherapy hematologic data
All patients
N = 27
.
S
Numbers in parentheses indicate range of values seen.
b Lower limits of normal = 78 fi
C Normal controls = 35 1.3 g/dl
S
S
S
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Bone aluminum, % trabecular surface
Fig. 1. Correlation between pretherapy hemoglobin level and percent
of bone surface staining positive for aluminum. N = 28; r —0.50; P
<0.07.
S SS
S
n = 28
r= —0.50 5
P < 0.007
S
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Pre
DFO therapy
Fig. 2. Hemoglobin level before and after 44 weeks of DFO therapy.
Mean hemoglobin level in the 19 treated patients (large solid black
circles) increased from 9.8 0.5 to 10.7 0.6 g/dl (P < 0.05). This
mean increase was attributable to 8 patients with a sustained increase in
hemoglobin of 1.3—4.4 g/dl (responders; small closed circles). Hemo-
globin levels were not significantly affected in II patients (nonre-
sponders; open circles).
higher in the 24 dialysis patients studied (77 6.3 g/d1 RBC)
than in 18 normal subjects (60 4.0; P < 0.05). Fifteen patients
(62%) had values one standard deviation above the normal
mean and 6 were >100 gIdl. These elevations could not be
explained by iron deficiency since all but two patients had
adequate iron status, as defined by a serum ferritin >100 ng/ml
and/or the presence of normal iron stores in the bone marrow
before therapy. Since RBC protoporphyrin levels are higher in
younger red cells [23] and since RBC age is decreased in
hemodialysis patients [24, 25], the relationship between RBC
protoporphyrin and age-sensitive RBC enzymes were also
examined. While RBC protoporphyrin levels were directly
related to pyridoxine kinase activities (r = 0.50; P < 0.05),
correlations with hexokinase, glucose 6-phosphate dehydroge-
nase, pyruvate kinase, pyrimidine 5' nucleotidose and 6-phos-
phogluconate dehydrogenase activities were not statistically
significant.
Response to DFO treatment
In the 19 patients treated with DFO, there was a marked
improvement in the degree of aluminum overload (serum alu-
minum DFO 278 31 to 84 13 sglliter; bone surface
aluminum staining 66 4 to 15 5% and bone aluminum
content 112 12 to 54 4 mg/kg dry wt).
The mean hemoglobin level increased significantly from 9.8
0.5 to 10.7 0.6 g/dl (P < 0.05) in the 19 treated patients (Fig.
2). In contrast, no change in serial hemoglobin level was
observed in the three patients receiving placebo during the 44
Responders
Non-
responders
P
values
Years on dialysis 8 1 8 I NS
Androgen use during DFO 2/8 6/11 NS
Baseline serum Al pg/liter 85 15 61 9 NS
Final serum Al sg/liter 125 27 124 14 NS
Baseline serum Al g/literb 275 58 278 34 NS
Final serum Al jig/liter 73 24 92 14 NS
Baseline % bone surface Al % 62 =6 69 5 NS
Final % bone surface Al % 16 10 14 4 NS
Baseline Fe overload' 1/8 8/Il < 0.02
Polycystic kidney disease 5/8 1/11 < 0.05
Baseline erythropoeitin
level  26 units 7/8 2/11 < 0.01
week treatment protocol. When a significant rise in hemoglobin
was defined as a >1.0 g/dl increase on at least two successive
monthly determinations, only eight of the 19 treated patients
were considered to be responders. These patients had sustained
increases in hemoglobin of 1.3 to 4.4 gldl. One responder was
transfusion dependent prior to DFO therapy but required no
transfusions after the third month of therapy.
Responders were compared to nonresponders to see which
factors contributed to a positive hematopoietic response to
DFO. Mean age, years on dialysis and frequency of androgen
use were similar in both groups (Table 3). All measures of
aluminum burden both before and after DFO therapy were also
similar. The main differences noted between responders and
nonresponders were the degree of iron overload (higher in
nonresponders even when only nontransfused patients were
examined) and the frequency of polycystic kidney disease
(more frequent in responders; Table 3). Furthermore, RBC
protoporphyrin levels were higher in responders versus nonre-
sponders (Table 4). Because of the association between poly-
cystic kidney disease and a positive hematopoietic response,
baseline erythropoietin levels, known to be higher in patients
with polycystic kidney disease than in other types of renal
disease [261, were analyzed. Although baseline hemoglobin
concentrations were similar in both groups (10.0 0.4 in
responders and 9.6 0.6 in nonresponders), baseline erythro-
poeitin levels were significantly higher in responders (74 29
mU/mi) than in nonresponders (18 3; P < 0.05 mU/mI; normal
levels are 18 to 26 and increase to 60 to 150 mU/mI with
anemia). Erythropoeitin levels ranged between 18 and 268
mU/mI in responders with five patients having levels 40. In
contrast, only two of 11 nonresponders had levels 26 and none
had levels >31 mU/mi. There was a significant correlation (r =
0.65; P < 0.01) between the maximum hemoglobin response
and baseline erythropoeitin levels as depicted in Figure 3.
Changes in hematologic parameters
Changes in hematologic parameters are listed in Table 4.
Serum ferritin levels fell from 628 302 to 178 133 nglml in
responders (P < 0.005) and from 2052 585 to 1388 496
ng/ml, P < 0.005, in nonresponders. A trend toward iron
deficiency developed in five of eight responders and two of 11
Table 3. Differences between responders and nonresponders15
14
13
12
11
10
9
8
7
6
0-.-
P value by chi square analysis or Student's t-test
b Difference in serum aluminum level before versus 24 to 48 hours
after DFO
Serum ferritin 700 mg/mi; marrow Fe >3+
Post
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All treated
patientsN=19 RespondersN=8
Non-
respondersN=1l
Hemoglobin g/dl
Pre-DFO 9.8 0.5 9.98 0.4 9,6 0.7
Post-DFO 10.7 0.6k 12.7 0,5 9.3 0.4
MCV fi"
Pre-DFO 94 1 94 2 95 2
Post-DFO 95 2 93 3 96 2
MCHC g/dl'
Pre-DFO 31.0 0.3 30.5 0.5 31.3 0.3
Post-DFO 31.6 0.6 31.3 0.6 31.8 0.9
Red cell number
Pre-DFO 3.22 0.1 3.3 0.2 3.18 0.2
Post-DFO 3.59 0.2a 4.1 0.2 3.21 0.2
Reticulocyte index %
Pre-DFO 0.7 0.1 0.6 0.1 0.9 0.1
Post-DFO 1.5 0.3 1.3 0.2 1.1 0.2
ALAD U/g Hb
Pre-DFO 27 3 30 4 24 2
Post-DFO 22 2 24 3
RBC protoporphyrin jig/di
Pre-DFO 81 11 106 liC 63 10
Post-DFO 72 13 95 22 56 5
Responders defined as patients with a sustained rise in hemoglobin of
>1 g/dl during DFO therapy.
a P < 0.05 pre- vs. post-DFO by paired i-analysis
b There was a transient increase in MCV and MCHC within the first
4 to 6 months which was not sustained through the duration of the
treatment period.
c P < 0.05 between responders and nonresponders
nonresponders who experienced serum ferritin levels below 50
nglml on at least two occasions during therapy. Despite this
finding, mean RBC protoporphyrin values tended to decrease
after DFO therapy. In fact, levels fell by 25 to 50% in seven of
eight patients in whom pretherapy values were elevated above
normal and in whom pre- and post-values were available. Mean
ALAD activity was not affected by DFO therapy.
Discussion
The current study supports previous reports [7, 9, 13, 14]
demonstrating an improvement in anemia with DFO therapy
even in patients with modest degrees of aluminum overload.
Although neither severe anemia nor microcytosis was observed
pretherapy, a contribution of aluminum overload to anemia is
strongly suggested by both the direct correlation between
hemoglobin level and aluminum burden (Fig. 1) and by the rise
in hemoglobin level observed in some patients during chelation
therapy with DFO. The results suggest that aluminum overload
does indeed depress hematopoeisis in dialysis patients, but that
the severity of the anemia and microcytosis depends on the
degree of the aluminum overload. Data in this and previous
reports suggest that the mechanism of the anemia is due to a
decrease in red cell production. In vitro studies have demon-
strated an inhibitory effect of aluminum on several enzymes
important in erythroid and iron metabolism [27—291. In the
current study, elevated red cell protoporphyrin levels, not
explained by iron deficiency or younger aged red cells, were
demonstrated in 15 of 26 (62%) patients pretherapy. These
elevations decreased by 25 to 50% in seven of eight patients in
whom pre- and post-DFO levels were available, an impressive
fall considering the tendency to develop iron deficiency with
DFO treatment. The data support those reported in previous
studies [8, 14] and suggest that aluminum overload causes a
reversible block in heme synthesis due either to a defect in
porphyrin synthesis or impaired iron utilization. In fact, the
greater elevation of RBC protoporphyrin levels in responders
suggests that the more severe the defect, the more likely a
patient is to respond to DFO.
Although we observed no correlation between baseline he-
moglobin concentration and either baseline serum aluminum
levels, serum aluminum levels after DFO or bone aluminum
content, a finding similar to previous studies [7, 8, 13, 30], there
was a significant correlation between hemoglobin and bone
surface staining for aluminum (Fig. 1). Stainable aluminum at
the mineralization front has also been demonstrated to reflect
histopathologic changes found in bone of dialyzed patients
better than bone aluminum content [31]. The current findings
provide additional support for the unique importance of the
degree of bone surface aluminum staining as a marker not just
of bone but also erythron damage from aluminum overload.
Not all patients with aluminum overload experience a rise in
hemoglobin after successful chelation of aluminum. In our
study, a dramatic rise in hemoglobin of up to 4.4 g/dl occurred
in eight patients while no sustained increase was observed in
the remaining 11 (Fig. 2). Lack of response to DFO was not
explained by a greater degree of aluminum overload either
before or after treatment or by a higher frequency of use of
other hematinic agents such as androgens (Table 3). Since many
of the responders were patients with polycystic disease, we
suspected that higher erythropoietin levels in these patients
Table 4. Hematologic data before and after treatment with DFO S
.
. S
+5 -
S
÷4 (268)
I +3
C
.1)
a
+2
E
E
+1
0
-1 U
I I I I I I -J
0 20 40 60 80 100 260 280
Serum erythropoietin, mU/mi
Fig. 3. Correlation (r = 0.65; P < 0.01) between maximum increase in
hemoglobin level during DFO therapy and pretherapy serum erythro-
poietin levels in responders (closed circles) and nonresponders (closed
boxes). The patient with the initial erythropoietin level of 263 mU/mi
was excluded from the equation.
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could explain the results. Although erythropoietin levels were
inappropriately low for the degree of anemia, as expected with
renal failure [32, 331, levels in responders were significantly
higher than in nonresponders. Moreover, there was a significant
correlation between the maximum rise in hemoglobin and the
pretherapy erythropoeitin level (Fig. 3). These findings imply
that the presence of at least premissive amounts of erythropoi-
etin may be important in determining a positive hematopoietic
response to DFO. These results support the multifactorial
nature of anemia in dialysis patients and may explain why some
patients with aluminum overload do not experience an increase
in hemoglobin level after aluminum has been removed.
Because aluminum, like lead, is associated with anemia, the
question has been raised that red cell ALAD may also be
depressed in patients with aluminum overload. Furthermore,
aluminum interferes with ALAD activity in vitro [291. Previous
measurements of ALAD levels in dialysis patients have been
reported as being low [34] or normal [351. Our failure to
demonstrate a significant correlation between the low levels of
ALAD that we observed and any measure of aluminum burden,
as well as the lack of change in enzyme activity after successful
chelation therapy, indicates that factors other than aluminum
can inhibit this enzyme in dialysis patients. It is clear that
ALAD activity cannot be used as a marker for aluminum
induced anemia in dialysis patients as it is in patients with lead
toxicity.
In summary, our results demonstrate that, even in the ab-
sence of severe anemia or microcytosis, aluminum contributes
to anemia in dialysis patients, at least in part, by impairing iron
utilization. Hematopoietic toxicity from aluminum correlates
with bone surface staining for aluminum but not with other
measures of aluminum overload. Although elevated RBC pro-
toporphyrin levels, in the absence of iron deficiency, may be a
useful test to suggest aluminum induced anemia in dialysis
patients, serum activity of ALAD is not. Therapy with DFO
significantly improves anemia in patients when sufficient levels
of erythropoietin are present to stimulate erythropoiesis. Care
must be taken to replete iron stores during therapy to avoid iron
deficiency with treatment. Although the improvement in anemia
is associated with aluminum removal, the current results do not
exclude the possibility that DFO could improve anemia in
dialysis patients by a mechanism independent of its effect on
aluminum chelation.
Acknowledgments
This work was supported in part by a grant from the Ciba Geigy
Corporation. We are indebted to Mrs. Alice Ellison for her help as the
nurse coordinator for this study. We are also indebted to Dr. Jeanne
Miadenovic for her assistance and advice concerning the measurement
of erythropoietin levels. Lastly, we are indebted to Mrs. Anne Martin
for her careful preparation of this manuscript.
Reprint requests to Margaret Bia, M.D., Yale School of Medicine,
333 Cedar Street, P.O. Box 3333, New Haven, Connecticut 06510,
USA.
References
1. COBURN JW, NORRIS KC: Diagnosis of aluminum-related bone
disease and treatment of aluminum toxicity with Deferoxamine.
Semin Nephrol 6 (Suppl l):12—21, 1986
2. SHERRARD DJ: Aluminum and renal osteodystrophy. Semin Neph-
rol6:5—ll, 1986
3. ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis enceph-
alopathy syndrome. N EngI J Med 29:184—188, 1976
4. ELLIOT HL, MACDOUGALL Al, FELL GS: Aluminum toxicity
syndrome. Lancet 1:203, 1978
5. SHORT Al, WINNEY RJ, ROBSON JS: Reversible, microcytic hy-
pochrornic anemia in dialysis patients due to aluminum intoxica-
tion. Proc EDTA 17:226—223, 1980
6. O'HARE JA, MURNAGHAN DF: Reversal of aluminum-induced
anemia by a low aluminum dialysate. N Engl J Med 306:854—856,
1982
7. TIELMANS C, COLLART F, WENS R, SMEYERS-VERBEEKE J, VAN
HOOFF I, DEATwA M, VERBEELEN D: Improvement in anemia with
deferoxamine in hemodialysis patients with aluminum-induced
bone disease. Clin Nephrol 24:237—241, 1985
8. SCHWARTZ R, D0MBR0u5KI J, BURNATOWSKA-HLEDIN M, MAYOR
G: Microcytic anemia in dialysis patients: Reversible marker of
aluminum toxicity. Am J Kid Dis IX:2l7—223, 1987
9. DRUEKE TB, LACOUR B, TOUAM M, JUQUEL J-P, PRACOT J-J,
COURTNOT-WITMER G, GALLE G: Effect of aluminum on hemato-
poeisis. Kid mt 29 (Suppl 18):S45—S48, 1986
10. IHLE BU, BECKER GJ, KINCAID-SMITH PS: Clinical and biochem-
ical features of aluminum-related bone disease. Kidney mt 29
(Suppl 18):S80—S86, 1986
11. NoRRIS KC, CRooKs PW, NEBEKER GH, HERCZ G, MILLINER DS,
GERSZI K, SLATOPOLSKY E, ANDRESS D, SHERRARD DJ, COBURN
JW: Clinical and laboratory features of aluminum related bone
disease: Difference between sporadic and epidemic forms of the
syndrome. Am J Kid Dis VI:342—347, 1985
12. MALLUCHE H, SMITH AJ, ABREO K, FAUGERE: The use of defer-
oxamine in the management of aluminum accumulation in bone in
patients with renal failure. N Englf Med 311:140—144, 1984
13. ALTMANN F, PLOWMAN D, MARSH F, CUNNINGHAM: Aluminum
chelation therapy in dialysis patients: Evidence for inhibition of
hemaglobin synthesis by low levels of aluminum. Lancet 1:1012—
1015, 1988
14. DELASERNA FJ, GILSANZ F, RUILOPE L-M, PRAGA M, RoDIclo
J-L, ALCAzAR J-M: Improvement in erythropoeisis of chronic
haemodialysis patients with desferrioxamine. Lancet 1:1009—1011,
1988
15. MILLINER DS, NEBEKER HG, OTT 5, ANDRESS D, SHERRARD DJ,
ALFREY AC, SLATOPOLSKY EA, COBURN JW: Use of the deferox-
amine infusion test in the diagnosis of aluminum related osteodys-
trophy. Ann intern Med 101:775—780, 1984
16. ALFREY A: Aluminum metabolism in uremia. Neuro Toxicol 1:
43—53, 1980
17. MALLUCHE H, FAUGERE MC: Atlas of Mineralized Bone Histol-
ogy. Basil, Karger, 1986
18. HRUSKA KA, KOPELMAN R, RUTHERFORD E, KLAHR S,
SLATOPOLSKY EA: Metabolism of immunoreactive parathyroid
hormone in the dog. J C/in Invest 56:39—48, 1975
19. GARCIA J, EBBE SN, HOLLANDER L: Radioimmunoassay of eryth-
ropoietin: Circulating levels in normal and polycythemic human
beings. J Lab Clin Med 99:624—635, 1982
20. CooK JD, MARSAGLIA G, ESCHBACH JW, FUNK DD, FINCH CA:
Ferrokinetics: A biologic model for plasma iron exchange in man. J
Clin invest 49:197—205, 1970
21. WEISBERG JB, LIP5CHUTZ F, OsKI FA: Delta aminolevulinic acid
dehydratase activity in circulating blood cells: A sensitive labora-
tory test for the detection of childhood lead poisoning. N Engi J
Med 284:565—569, 1971
22. HELLER SR. LABBE RF, NUTFER J: A simplified assay for porphy-
rins in whole blood. C/in Chem 17:525—528, 1971
23. ANDERSON KE, SASSA S. PETERSON CM, KAPPA5 A: Increased
erythrocyte uroporphyrinogen I -synthetase, delta-aminolevulinic
acid dehydratase and proporphyrin in hemolytic anemias. Am J
Med 63:359—364, 1977
24. SOLOMON LR, HENDLER ED: Androgen therapy in hemodialysis
patients. II. Effects on red cell metabolism. Brit J Haematol
65:223—230, 1987
25. SHAW AB: Hemolysis in chronic renal failure. BrMedJ2:213—244,
1967
858 Bia et a!: Aluminum induced anemia
26. CHANDRA M, MILLER ME, GARCIA JF: Serum immunoreactive
erythropoietin levels in patients with polycystic kidney disease
compared with other dialysis patients. Nephron 39:26—29, 1985
27. TRAPP GA: Studies of aluminum interaction with enzymes and
proteins—The inhibition of hexokinase. Neuro Toxicol 1:89—100, 1980
28. HUBER CT, FRIEDEN E: The inhibitons of ferroxidase by trivalent
and other metals. J Biol Chem 245:3979—3984, 1970
29. MEREDITH PA, MOORE MR, GOLDERG A: Effects of aluminum,
lead and zinc on delta-aminolaevulenic acid dehydratase. Enzyme
22:22—27, 1977
30. ALTMAN P, AL-SALIHI F, BUTTER K, CUTLER P, BLAIR J, LEEM-
ING R, CUNNINGHAM J, MARSH F: Serum aluminum levels and
erythrocyte dihydropteridine reductase activity in patients on he-
modialysis. N EngI J Med 317:80—84, 1987
31. FAUGERE MC, MALLUCI-IL HH: Stainable aluminum and not alu-
minum content reflects bone histology in dialyzed patients. Kidney
mt 30:717—722, 1986
32. MCGONIGLE RJS, WALLIN JD, SHADDUCH RK: Erythropoietin
deficiency and inhibition of erythropoiesis in renal insufficiency.
Kidney mt 25:437—444, 1984
33. KAISER L, SCHWARTZ K: Aluminum-induced anemia. Am J Kid
Dis VI:348—352, 1985
34. MEREDITH PA, ELLIOTT HL, CAMPBELL BC, MooRE MR:
Changes in serum aluminum, blood zinc, blood lead and erythro-
cyte delat-aminolaevulinie acid dehydratase activity during haemo-
dialysis. Toxicol Left 4:419—424, 1979
35. MCGONIGLE RJS, PARSONS V: Aluminum-induced anemia in he-
modialysis patients. Nephron 39:1—9, 1985
